How should a nephrologist manage an adult with intermittent renal calculi, hypertension, hypertensive epistaxis, prior urinary‑tract infection, and slowly worsening impaired renal function (serum creatinine 1.6 mg/dL, baseline 1.2 mg/dL), who is taking low‑dose aspirin and CILACAR‑T, with elevated blood pressure (140/90 mmHg) and hypertriglyceridemia?

Nephrologic Management of Chronic Kidney Disease with Recurrent Nephrolithiasis and Uncontrolled Hypertension

Add amlodipine 5 mg daily to the current regimen of lisinopril (CILACAR-T) and continue low-dose aspirin; target blood pressure <130/80 mmHg, obtain a urine albumin-to-creatinine ratio, and implement dietary sodium restriction to <2.3 g/day. 1

---

Blood Pressure Management

Current Status & Target

• The patient's BP of 140/90 mmHg exceeds the recommended target of <130/80 mmHg for all CKD patients, which reduces cardiovascular mortality and slows CKD progression. 1, 2
• CILACAR-T contains telmisartan (an ARB) plus chlorthalidone (a thiazide-like diuretic); this combination provides renin-angiotensin system blockade plus diuretic therapy. 1

Second-Line Antihypertensive Agent

• Add amlodipine 5 mg once daily as the second-line agent; dihydropyridine calcium channel blockers provide superior BP control and greater renoprotection than adding additional diuretics in stage 3 CKD patients already on an ACE inhibitor or ARB. 1
• Titrate amlodipine to 10 mg daily if BP remains above target after 2–4 weeks. 1
• Thiazide diuretics lose efficacy when eGFR falls below 30–40 mL/min/1.73 m²; the patient's current creatinine of 1.6 mg/dL (estimated eGFR ~45–50 mL/min/1.73 m² for a 75 kg adult) means the chlorthalidone component of CILACAR-T remains effective, but a CCB offers additive benefit. 1, 3

Monitoring After Adding Amlodipine

• Measure serum creatinine and eGFR within 4 weeks of adding amlodipine. 1
• Check serum potassium within 4 weeks given concurrent ARB therapy. 1
• Monitor office BP every 2–4 weeks until target is achieved, then every 3–6 months once stable. 1
• Do not discontinue the ARB if creatinine rises ≤30% within 4 weeks; this hemodynamic effect is associated with long-term renoprotection. 1

---

Albuminuria Assessment & Additional Renoprotective Therapy

Obtain Urine Albumin-to-Creatinine Ratio (UACR)

• Order a spot urine UACR to stratify cardiovascular and CKD progression risk; this test is recommended for all CKD patients by KDIGO and ACC/AHA. 1, 4
• If UACR ≥200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) to reduce CKD progression by 39–44% and major cardiovascular events by ~29%. 1
• SGLT2 inhibitors can be initiated at eGFR ≥20 mL/min/1.73 m² and provide benefit even in non-diabetic CKD with albuminuria. 1

---

Dietary Sodium Restriction

• Advise dietary sodium intake <2.3 g/day (≈100 mmol/day) to maximize the antihypertensive and antialbuminuric effects of the ARB and any added agents. 1, 2
• Sodium restriction synergistically enhances BP-lowering efficacy of renin-angiotensin system blockers and reduces proteinuria. 1, 3

---

Management of Recurrent Nephrolithiasis

Fluid Intake & Dietary Modification

• Increase fluid intake to achieve urine output >2.5 L/day; this is the single most effective intervention to prevent recurrent calcium stones. 5
• Reduce dietary sodium (as above) and avoid low dietary calcium; paradoxically, adequate dietary calcium (1000–1200 mg/day) reduces stone risk by binding oxalate in the gut. 5
• Reduce animal protein intake to <0.8–1.0 g/kg/day; excessive animal protein increases urinary calcium and uric acid excretion. 5

Pharmacologic Stone Prevention

• Thiazide diuretics (already present in CILACAR-T as chlorthalidone) reduce recurrent calcium stone risk more than increased fluid intake alone. 5
• Potassium citrate 30–60 mEq/day (divided doses) reduces recurrent calcium stone risk by alkalinizing urine and increasing urinary citrate; consider adding if stone recurrence continues despite thiazide therapy. 5
• Allopurinol 100–300 mg daily reduces recurrent calcium stones in patients with hyperuricosuria or hyperuricemia; check serum uric acid and 24-hour urine uric acid to guide this decision. 5

Stone Composition & Metabolic Evaluation

• Obtain stone analysis if a stone is passed or retrieved; stone composition guides targeted therapy (e.g., allopurinol for uric acid stones, potassium citrate for calcium oxalate stones). 5
• Consider 24-hour urine collection for calcium, oxalate, citrate, uric acid, sodium, and creatinine to identify metabolic abnormalities driving stone formation. 5
• The evidence for extensive biochemical evaluation is limited, but tailored dietary and pharmacologic interventions based on metabolic abnormalities may reduce recurrence. 5

---

Low-Dose Aspirin Continuation

Renal Effects of Aspirin in CKD

• Continue aspirin 75 mg daily for cardiovascular protection; low-dose aspirin reduces coronary events and may slow renal disease progression in CKD patients without prior cardiovascular events. 6
• Aspirin may cause transient retention of uric acid and creatinine in elderly patients, but the patient's stable creatinine trend (1.6 mg/dL in [DATE], previously 1.2 mg/dL) suggests no acute aspirin-related nephrotoxicity. 7
• Monitor serum creatinine every 3–6 months to detect any delayed renal effects; 48% of elderly patients on low-dose aspirin have persistent decline in creatinine clearance 3 weeks after stopping aspirin, but this does not mandate discontinuation in the absence of acute kidney injury. 7

Cardiovascular Risk Reduction

• The patient has hypertension, hypertensive epistaxis, and elevated triglycerides (183 mg/dL), all of which increase cardiovascular risk; aspirin provides primary prevention benefit in this context. 6
• No major bleeding was reported in the AASER trial of aspirin in CKD patients, and minor bleeding episodes were similar between aspirin and control groups. 6

---

Hypertriglyceridemia Management

Current Triglyceride Level

• Triglycerides of 183 mg/dL are elevated (normal <150 mg/dL) and contribute to cardiovascular risk in CKD patients. 8
• Hypertriglyceridemia in CKD is multifactorial, driven by reduced lipoprotein lipase activity, increased hepatic VLDL production, and impaired clearance of triglyceride-rich lipoproteins. 8

Lifestyle Modification

• Recommend weight loss if BMI >25 kg/m² (current weight 75.75 kg; calculate BMI based on height). 2
• Reduce saturated fat intake and limit alcohol to moderate intake (≤1 drink/day for men). 2
• Increase physical activity to 150 minutes/week of moderate-intensity exercise. 2

Pharmacologic Therapy

• Consider statin therapy (e.g., atorvastatin 10–20 mg daily) if triglycerides remain >200 mg/dL or if LDL cholesterol is elevated; statins reduce cardiovascular events in CKD patients. 8
• Fibrates (e.g., fenofibrate) are an alternative for isolated hypertriglyceridemia, but require dose adjustment in CKD and carry a risk of rhabdomyolysis when combined with statins. 8

---

Monitoring Plan

Renal Function

• Measure serum creatinine, eGFR, and electrolytes every 3–6 months in stage 3 CKD. 1, 4
• Obtain UACR annually or more frequently if albuminuria is present. 1, 4
• Use creatinine-cystatin C combined equations (e.g., CKD-EPI 2021 or EKFC) for more accurate eGFR estimation if cystatin C is available. 4

Blood Pressure

• Home BP monitoring is recommended to detect white-coat hypertension and improve BP control; target <130/80 mmHg at home. 2, 9
• Office BP every 2–4 weeks until target is achieved, then every 3–6 months. 1

Stone Recurrence

• Annual imaging (ultrasound or low-dose CT) to detect asymptomatic stone growth if recurrent stones are a concern. 5
• 24-hour urine collection 6–12 months after initiating dietary and pharmacologic stone prevention to assess treatment efficacy. 5

---

Common Pitfalls to Avoid

• Do not add an ACE inhibitor to the current ARB (telmisartan in CILACAR-T); dual RAAS blockade increases hyperkalemia and acute kidney injury risk without added benefit. 1
• Do not discontinue the ARB if creatinine rises ≤30% within 4 weeks of adding amlodipine; this hemodynamic effect is expected and associated with long-term renoprotection. 1
• Do not use NSAIDs (e.g., ibuprofen, naproxen) for pain management in this patient; NSAIDs worsen renal function in CKD and increase cardiovascular risk. 10
• Do not rely solely on thiazide diuretics for BP control if eGFR falls below 30 mL/min/1.73 m²; switch to a loop diuretic (furosemide 20–40 mg daily) at that stage. 1, 11
• Do not use nitrofurantoin or sulfamethoxazole for UTI treatment if creatinine clearance is <50 mL/min; these drugs achieve inadequate urine concentrations and are ineffective. 12
• Do not overlook family history of nephrolithiasis in the patient's children (ages 13 and 17); consider genetic evaluation for hereditary stone disorders (e.g., cystinuria, primary hyperoxaluria) if stones recur frequently. 5

---

Summary of Immediate Actions

1. Add amlodipine 5 mg daily to current regimen. 1
2. Order spot urine albumin-to-creatinine ratio. 1, 4
3. Advise dietary sodium <2.3 g/day and adequate dietary calcium (1000–1200 mg/day). 5, 1
4. Increase fluid intake to achieve urine output >2.5 L/day. 5
5. Continue aspirin 75 mg daily. 6
6. Measure serum creatinine, eGFR, and potassium in 4 weeks. 1
7. Check BP in 2–4 weeks; titrate amlodipine to 10 mg if BP remains >130/80 mmHg. 1
8. Consider statin therapy if triglycerides remain elevated or LDL is high. 8
9. Obtain stone analysis if a stone is passed. 5
10. Consider 24-hour urine collection for metabolic stone evaluation. 5